目前，虽然基因编辑疗法为 DMD 的治疗带来了一丝希望，但临床应用的道路上仍布满荆棘，比如难以确定临床疗效、无法有效控制潜在的脱靶效应等。而糖皮质激素（如地夫可特、泼尼松）虽能延缓疾病进展，却也伴随着肥胖、行为改变、身材矮小和骨质减少等诸多副作用，就像 “饮鸩止渴”，让患者陷入两难境地。因此，寻找更安全有效的治疗方法，成为了医学领域亟待攻克的难题。

Having found that in biomedical research, the Bird Rock resident and scientist at La Jolla’s Sanford Burnham Prebys has ...

Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where ...

Dominic Olsen is a bright and determined 10-year-old boy living with Duchenne Muscular Dystrophy, a rare disease that has ...

Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature ...

Researchers combined advanced imaging techniques and theoretical physics to observe and explain how nanoclusters of the protein emerin form inside living cells. The study uncovers the molecular 'rules ...

A new discovery about how tiny protein clusters form in cells could pave the way for treatments for Emery-Dreifuss muscular ...

Roland Beres sits down with April Gannon of the Muscular Dystrophy Association to discuss the importance of raising money and ...

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and ...